IINN
Inspira Technologies Oxy B.H.N. Ltd.
Medical - Devices
Market Cap$11M
5Y Perf.-88.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
IINN vs LUNG
Revenue, margins, valuation, and 5-year total return — side by side.
LUNG
Pulmonx Corporation
Medical - Devices
Market Cap$54M
5Y Perf.-96.8%
IINN vs LUNG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | IINN | LUNG |
|---|---|---|
| Industry | Medical - Devices | Medical - Devices |
| Market Cap | $11M | $54M |
| Revenue (TTM) | $289K | $90M |
| Net Income (TTM) | $-13M | $-54M |
| Gross Margin | 0.7% | 74.2% |
| Operating Margin | 45.1% | -59.3% |
| Total Debt | $3M | $56M |
| Cash & Equiv. | $5M | $70M |
IINN vs LUNG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
IINN
LUNG
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Inspira Technologie… (IINN) | 100 | 11.5 | -88.5% |
| Pulmonx Corporation (LUNG) | 100 | 3.2 | -96.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IINN vs LUNG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LUNG leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Inspira Technologies Oxy B.H.N. Ltd. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
IINN
Inspira Technologies Oxy B.H.N. Ltd.
The Income Pick
IINN is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.52
- EPS growth 99.9%
- -90.5% 10Y total return vs LUNG's -96.8%
Best for: income & stability and growth exposure
LUNG
Pulmonx Corporation
The Growth Leader
LUNG carries the broadest edge in this set and is the clearest fit for growth and quality.
- 8.0% revenue growth vs IINN's -16.1%
- -59.7% margin vs IINN's -43.7%
- -38.2% ROA vs IINN's -275.8%, ROIC -72.0% vs 0.5%
Best for: growth and quality
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | LUNG | 8.0% revenue growth vs IINN's -16.1% |
| Quality / Margins | LUNG | -59.7% margin vs IINN's -43.7% |
| Stability / Safety | IINN | Beta 1.52 vs LUNG's 2.36, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IINN | -16.3% vs LUNG's -65.5% |
| Efficiency (ROA) | LUNG | -38.2% ROA vs IINN's -275.8%, ROIC -72.0% vs 0.5% |
IINN vs LUNG — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIINNLAGGINGLUNG
LUNGPulmonx Corporation
0leads
IINNInspira Technologies …
1leads
6 Total Categories
CATEGORYLEADERvs LUNGMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
IINN5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — IINN and LUNG each lead in 2 of 4 comparable metrics.
Income & Cash Flow (Last 12 Months)
LUNG is the larger business by revenue, generating $90M annually — 313.1x IINN's $289,000. Profitability is closely matched — net margins range from -59.7% (LUNG) to -43.7% (IINN).
| Metric | IINNInspira Technolog… | LUNGPulmonx Corporati… |
|---|---|---|
| RevenueTrailing 12 months | $289,000 | $90M |
| EBITDAEarnings before interest/tax | $13M | -$53M |
| Net IncomeAfter-tax profit | -$13M | -$54M |
| Free Cash FlowCash after capex | $0 | -$33M |
| Gross MarginGross profit ÷ Revenue | +0.7% | +74.2% |
| Operating MarginEBIT ÷ Revenue | +45.1% | -59.3% |
| Net MarginNet income ÷ Revenue | -43.7% | -59.7% |
| FCF MarginFCF ÷ Revenue | — | -36.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -4.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +36.8% | +24.2% |
Evenly matched — IINN and LUNG each lead in 2 of 4 comparable metrics.
Valuation Metrics
Evenly matched — IINN and LUNG each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | IINNInspira Technolog… | LUNGPulmonx Corporati… |
|---|---|---|
| Market CapShares × price | $11M | $54M |
| Enterprise ValueMkt cap + debt − cash | $8M | $40M |
| Trailing P/EPrice ÷ TTM EPS | -750.00x | -0.95x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 726.48x | — |
| Price / SalesMarket cap ÷ Revenue | — | 0.59x |
| Price / BookPrice ÷ Book value/share | 1.93x | 0.95x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — IINN and LUNG each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — IINN and LUNG each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
LUNG delivers a -82.8% return on equity — every $100 of shareholder capital generates $-83 in annual profit, vs $-4 for IINN. IINN carries lower financial leverage with a 0.58x debt-to-equity ratio, signaling a more conservative balance sheet compared to LUNG's 1.04x. On the Piotroski fundamental quality scale (0–9), LUNG scores 3/9 vs IINN's 1/9, reflecting mixed financial health.
| Metric | IINNInspira Technolog… | LUNGPulmonx Corporati… |
|---|---|---|
| ROE (TTM)Return on equity | -3.7% | -82.8% |
| ROA (TTM)Return on assets | -2.8% | -38.2% |
| ROICReturn on invested capital | +0.5% | -72.0% |
| ROCEReturn on capital employed | +0.2% | -43.3% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 |
| Debt / EquityFinancial leverage | 0.58x | 1.04x |
| Net DebtTotal debt minus cash | -$3M | -$14M |
| Cash & Equiv.Liquid assets | $5M | $70M |
| Total DebtShort + long-term debt | $3M | $56M |
| Interest CoverageEBIT ÷ Interest expense | — | -16.55x |
Evenly matched — IINN and LUNG each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
IINN leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IINN five years ago would be worth $947 today (with dividends reinvested), compared to $298 for LUNG. Over the past 12 months, IINN leads with a -16.3% total return vs LUNG's -65.5%. The 3-year compound annual growth rate (CAGR) favors IINN at -31.8% vs LUNG's -53.3% — a key indicator of consistent wealth creation.
| Metric | IINNInspira Technolog… | LUNGPulmonx Corporati… |
|---|---|---|
| YTD ReturnYear-to-date | -51.1% | -44.8% |
| 1-Year ReturnPast 12 months | -16.3% | -65.5% |
| 3-Year ReturnCumulative with dividends | -68.3% | -89.8% |
| 5-Year ReturnCumulative with dividends | -90.5% | -97.0% |
| 10-Year ReturnCumulative with dividends | -90.5% | -96.8% |
| CAGR (3Y)Annualised 3-year return | -31.8% | -53.3% |
IINN leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — IINN and LUNG each lead in 1 of 2 comparable metrics.
Risk & Volatility
IINN is the less volatile stock with a 1.52 beta — it tends to amplify market swings less than LUNG's 2.36 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LUNG currently trades 32.7% from its 52-week high vs IINN's 27.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IINNInspira Technolog… | LUNGPulmonx Corporati… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.52x | 2.36x |
| 52-Week HighHighest price in past year | $1.65 | $3.88 |
| 52-Week LowLowest price in past year | $0.34 | $1.13 |
| % of 52W HighCurrent price vs 52-week peak | +27.3% | +32.7% |
| RSI (14)Momentum oscillator 0–100 | 40.9 | 45.5 |
| Avg Volume (50D)Average daily shares traded | 292K | 567K |
Evenly matched — IINN and LUNG each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | IINNInspira Technolog… | LUNGPulmonx Corporati… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IINN leads in 1 of 6 categories — strongest in Total Returns. 4 categories are tied.
Best OverallInspira Technologies Oxy B.… (IINN)Leads 1 of 6 categories
Loading custom metrics...
IINN vs LUNG: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — IINN or LUNG?
Over the past 5 years, Inspira Technologies Oxy B.
H. N. Ltd. (IINN) delivered a total return of -90. 5%, compared to -97. 0% for Pulmonx Corporation (LUNG). Over 10 years, the gap is even starker: IINN returned -90. 5% versus LUNG's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — IINN or LUNG?
By beta (market sensitivity over 5 years), Inspira Technologies Oxy B.
H. N. Ltd. (IINN) is the lower-risk stock at 1. 52β versus Pulmonx Corporation's 2. 36β — meaning LUNG is approximately 55% more volatile than IINN relative to the S&P 500. On balance sheet safety, Inspira Technologies Oxy B. H. N. Ltd. (IINN) carries a lower debt/equity ratio of 58% versus 104% for Pulmonx Corporation — giving it more financial flexibility in a downturn.
03Which is growing faster — IINN or LUNG?
On earnings-per-share growth, the picture is similar: Inspira Technologies Oxy B.
H. N. Ltd. grew EPS 99. 9% year-over-year, compared to 7. 6% for Pulmonx Corporation. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — IINN or LUNG?
Pulmonx Corporation (LUNG) is the more profitable company, earning -59.
7% net margin versus -43. 7% for Inspira Technologies Oxy B. H. N. Ltd. — meaning it keeps -59. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IINN leads at 45. 1% versus -59. 3% for LUNG. At the gross margin level — before operating expenses — LUNG leads at 74. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — IINN or LUNG?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is IINN or LUNG better for a retirement portfolio?
For long-horizon retirement investors, Inspira Technologies Oxy B.
H. N. Ltd. (IINN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Pulmonx Corporation (LUNG) carries a higher beta of 2. 36 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IINN: -90. 5%, LUNG: -96. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between IINN and LUNG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.